American Century Companies Inc. Acquires 24,197 Shares of OmniAb, Inc. $OABI

American Century Companies Inc. boosted its holdings in OmniAb, Inc. (NASDAQ:OABI) by 15.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 181,408 shares of the company’s stock after purchasing an additional 24,197 shares during the quarter. American Century Companies Inc.’s holdings in OmniAb were worth $435,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OABI. Wells Fargo & Company MN boosted its position in shares of OmniAb by 24.3% during the fourth quarter. Wells Fargo & Company MN now owns 62,859 shares of the company’s stock worth $223,000 after acquiring an additional 12,278 shares during the last quarter. Barclays PLC boosted its holdings in shares of OmniAb by 14.7% during the 4th quarter. Barclays PLC now owns 164,315 shares of the company’s stock valued at $582,000 after purchasing an additional 21,100 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in shares of OmniAb by 4.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 3,025,674 shares of the company’s stock valued at $10,711,000 after purchasing an additional 142,513 shares during the last quarter. Hsbc Holdings PLC bought a new position in shares of OmniAb during the 4th quarter valued at about $38,000. Finally, Price T Rowe Associates Inc. MD boosted its holdings in shares of OmniAb by 26.3% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 38,217 shares of the company’s stock valued at $136,000 after purchasing an additional 7,950 shares during the last quarter. Institutional investors own 72.08% of the company’s stock.

OmniAb Stock Up 6.9%

Shares of OABI opened at $1.71 on Friday. The company has a market cap of $209.82 million, a PE ratio of -2.85 and a beta of 0.14. The business has a fifty day moving average of $1.90 and a 200 day moving average of $2.04. OmniAb, Inc. has a 52-week low of $1.22 and a 52-week high of $4.87.

OmniAb (NASDAQ:OABI) last released its earnings results on Wednesday, August 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $3.90 million during the quarter, compared to the consensus estimate of $5.33 million. OmniAb had a negative return on equity of 22.79% and a negative net margin of 275.83%. As a group, research analysts anticipate that OmniAb, Inc. will post -0.61 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on OABI shares. Royal Bank Of Canada dropped their price target on OmniAb from $4.00 to $3.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Benchmark reiterated a “buy” rating and set a $6.00 target price on shares of OmniAb in a research report on Monday, May 12th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, OmniAb presently has a consensus rating of “Buy” and a consensus target price of $6.67.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.